Mandalá, Mario http://orcid.org/0000-0001-8846-8959
Larkin, James
Ascierto, Paolo A http://orcid.org/0000-0002-8322-475X
Del Vecchio, Michele
Gogas, Helen http://orcid.org/0000-0002-0451-2885
Cowey, C Lance
Arance, Ana
Dalle, Stéphane
Schenker, Michael
Grob, Jean-Jacques
Chiarion-Sileni, Vanna
Marquez-Rodas, Ivan http://orcid.org/0000-0002-2476-668X
Butler, Marcus O
Di Giacomo, Anna Maria
Lutzky, Jose http://orcid.org/0000-0002-9503-2130
De La Cruz-Merino, Luis
Atkinson, Victoria
Arenberger, Petr
Hill, Andrew
Fecher, Leslie
Millward, Michael
Khushalani, Nikhil I
de Pril, Veerle
Lobo, Maurice
Weber, Jeffrey http://orcid.org/0000-0002-4962-2957
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vedolizumab: a novel treatment for ipilimumab-induced colitis
https://doi.org/10.1136/bcr-2016-216641
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
https://doi.org/10.1200/jco.23.01448
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.
https://doi.org/10.1200/jco.2023.41.16_suppl.9577
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
https://doi.org/10.1136/jitc-2021-003188
308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
https://doi.org/10.1136/jitc-2020-sitc2020.0308
Documents that mention this clinical trial
Vedolizumab: a novel treatment for ipilimumab-induced colitis
https://doi.org/10.1136/bcr-2016-216641
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
https://doi.org/10.1200/jco.23.01448
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.
https://doi.org/10.1200/jco.2023.41.16_suppl.9577
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
https://doi.org/10.1136/jitc-2021-003188
308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
https://doi.org/10.1136/jitc-2020-sitc2020.0308
Funding for this research was provided by:
Bristol Myers Squibb